Gene Solutions Welcomes Evan Greger as Strategic Advisor to the Board of Directors
Gene Solutions, a pioneering genetic testing company in Asia, today announced the appointment of Evan Greger, M.Sc. and M.B.A., an experienced biotechnology and life sciences leader, as a Strategic Advisor to the Board of Directors. Evan brings nearly 30 years of diverse experience in the biotechnology and life sciences industry, enhancing our strategic vision and leadership team.
Dr. Nghia Nguyen, Ph.D., CEO & Co-founder of Gene Solutions, shares: “Our mission dives into advancing precision cancer care by unlocking the full potential of Multi-omics Insights and Bioinformatic Artificial Intelligence. Evan Greger’s diverse background, global exposure, and proven track record in the successful development and commercialization of novel therapies and services will provide significant value as we strive to achieve our growth and development goals. His deep strategic and operational expertise will enhance the technical excellence of our leadership team and provide Gene Solutions with the strategic insights and operational leadership required to serve our patients and enhance our profile in the clinical genomics industry. We warmly welcome Evan as a Strategic Advisor to our Board of Directors and look forward to his contributions in advancing Gene Solutions’ mission.”
Evan Greger’s career has focused on the development and commercialization of innovative therapies, generating value and patient benefits in emerging startups and pharmaceutical companies. His expertise spans diverse modalities, including cell therapies, monoclonal antibodies, recombinant proteins, and vaccines, with repeated success in bringing medicines to patients.
Evan joins Gene Solutions from Pionyr Immunotherapeutics, where he served as Chief Technical Officer and Senior Vice President of Technical Operations, advancing two novel oncology antibodies into the clinic. Prior to this, he worked for three industry leaders in CAR T autologous therapy. At Cell Design Labs (acquired by Kite Pharma/Gilead Sciences), he was Vice President of Process Development and CMC, developing an overarching CMC strategy for next-generation viral vector technology. At Juno Therapeutics (acquired by Celgene/BMS), he was Senior Director of Technical Operations, establishing EU operations to globalize Breyanzi® and creating JW Therapeutics manufacturing operations in Asia with WuXi AppTec. At Novartis in Basel, Switzerland, he was the Global Head of Manufacturing Sciences and Technology, Biopharmaceutical Operations, expanding a team across five international sites and contributing to the commercialization of the CAR T therapy Kymriah® and life cycle activities for Cosentyx®, Ilaris®, and Simulect®.
Earlier in his career, Evan worked for nine years at Amgen, driving Enbrel® process validation and the successful licensure of seven international manufacturing facilities, directing the CMC regulatory filing for Vectibix®, and progressing two biosimilars (Amjevita® and Mivasi®) into clinical trials. At Aventis (acquired by Sanofi Pasteur), he managed the alliance with Merck for the hexavalent vaccine Vaxelis® and performed legacy validation on adult and pediatric vaccines.
In 2021, while working at Pionyr Immunotherapeutics, Evan founded Bionnassay LLC, a global consulting practice that provides strategic consulting services to innovative startups, companies, and venture capital firms. Additionally, Evan works as a consultant with Alira Health, a patient-centric and technology-enabled advisory firm that supports healthcare and life sciences organizations across the commercial life cycle. His consultancy focus reflects his commitment to generating value, benefiting patients, and successfully developing innovative therapies to improve global human health.
Throughout his extensive career, Evan has demonstrated a broad spectrum of leadership and organizational skills and developed deep expertise in technical operations across the entire supply chain. His experience will be invaluable as Gene Solutions solidifies its position as a leading genetic testing provider in Asia.
“Gene Solutions has developed a unique genetic testing portfolio for both reproductive health and clinical oncology, notably pioneering circulating tumor DNA technology for early cancer detection and minimal residual disease tracking. The firm is transforming cancer care in the region with deep genomics data mining, sophisticated bio-modeling, and multi-dimensional artificial intelligence,” said Evan. “I am excited to work closely with the Gene Solutions leadership team to apply my strategic and technical operations experience in novel drug discovery for biopharma solutions and expanding global testing services”.
At Gene Solutions, we are excited about the upcoming development and global exposure that Evan Greger will strategically direct. Follow our website and social media for more updates on our people and science.
About Gene Solutions:
Gene Solutions is a pioneering and prominent genetic testing company in Asia, dedicated to developing and providing access to next-generation genetic testing. The company supports:
- Reproductive Health: Offering unique Non-invasive Prenatal Testing (NIPT) that integrates screening for Recessive and Dominant Single-Gene Disorders.
- Clinical Oncology: Including Multi-cancer Early Detection (MCED), Comprehensive Genomic Profiling (CGP) for precision therapy selection, and Minimal Residual Disease (MRD) tracking using circulating tumor DNA (ctDNA) technology.
Gene Solutions envisions empowering healthcare in the region through advanced genomics and multi-dimensional artificial intelligence. With over 1.5 million tests provided to patients, the company demonstrates its commitment to accessible genetic testing services
